Quantcast

Latest Oncotype DX Stories

2014-05-16 16:24:58

Oncotype DX® Prostate Cancer Test Enables More Precise Risk Assessment and Significantly Increases Number of Low-Risk Patients Who Can Confidently Choose Active Surveillance REDWOOD CITY, Calif., May 16, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) announced today that groundbreaking results from three studies of the Oncotype DX(®) prostate cancer test were published in European Urology. The peer-reviewed publication highlights studies that focus on addressing the need...

2014-05-14 08:31:12

Centralized database of gene-based tests enables easy access to information, improves transparency REDWOOD CITY, Calif., May 14, 2014 /PRNewswire/ -- In response to continued advances in genomic technology and genetic medicine, the National Institutes of Health (NIH) has developed the Genetic Testing Registry (GTR), a free online resource, to provide physicians, researchers and patients with detailed and accurate information about genetic and genomic tests. Comprehensive scientific...

2014-05-13 23:15:54

The Diagnostics Marketing Association (DxMA) hosted their annual Global Marketing Summit and Dx Creative Communications Awards Ceremony last month in San Francisco, CA. Representatives from close to 50 different diagnostic companies were in attendance. Indianapolis, IN (PRWEB) May 13, 2014 The Diagnostics Marketing Association (DxMA) hosted their annual Global Marketing Summit and Dx Creative Communications Awards Ceremony last month in San Francisco, CA. Representatives from close to 50...

2014-05-06 16:32:54

13% Increase in Test Volume and 7% Increase in Product Revenue Compared to Prior Year REDWOOD CITY, Calif., May 6, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter ended March 31, 2014. Logo - http://photos.prnewswire.com/prnh/20130425/SF01493LOGO Product revenue was $67.0 million in the first quarter of 2014, compared with $62.7 million for the first quarter of 2013, an increase of 7 percent. Total revenue for...

2014-05-05 08:28:31

New Data Include Results on Oncotype DX's Prognosis of Late Recurrence in Invasive Breast Cancer and Clinical Utility in Ductal Carcinoma In Situ (DCIS) REDWOOD CITY, Calif., May 5, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that results from nine studies of Oncotype DX(®) in breast, colon, prostate and renal cancer will be presented at the American Society of Clinical Oncology(®) (ASCO(®)) Annual Meeting, taking place May 30 - June 3, 2014 at McCormick Place...

2014-05-02 08:25:16

Large Study Published in The Oncologist Underscores Test's Value in Guiding Treatment Decisions REDWOOD CITY, Calif., May 2, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that The Oncologist published positive results from an Oncotype DX(®) colon cancer decision impact study, demonstrating that Recurrence Score(®) results changed treatment recommendations in 45 percent of stage II colon cancer patients. The study was conducted in collaboration with the...

2014-04-29 08:35:57

REDWOOD CITY, Calif., April 29, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will host a conference call and webcast on Tuesday, May 6 at 4:30 p.m. Eastern Time to discuss its first quarter 2014 financial results. The call and webcast will follow the release of the first quarter financial results after market close. http://photos.prnewswire.com/prnvar/20130425/SF01493LOGO Conference Call DetailsTo access the live conference call on May 6...

2014-04-22 08:33:21

Expanded Reimbursement in Canada and Inclusion in Leading German Physician Guidelines Increase Genomic Health's Impact in Key International Markets REDWOOD CITY, Calif., April 22, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced two important international milestones including additional reimbursement in Canada and the inclusion of the Oncotype DX(®) breast cancer test in major German clinical guidelines. In Canada, the BC Cancer Agency in British Columbia...

2014-03-19 08:29:07

Data Presented at 9th European Breast Cancer (EBCC-9) Symposium Highlights Comprehensive Body of Clinical Evidence for Oncotype DX REDWOOD CITY, Calif., March 19, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the presentation of multiple Oncotype DX® breast cancer studies at the 9(th) European Breast Cancer Conference (EBCC-9), which takes place March 19-21 in Glasgow, Scotland, United Kingdom. New data will include an independently conducted physician survey that...

2014-03-06 23:23:25

Genomic Health Successfully Launched a Viral Educational Concept for Reaching People Touched by Breast Cancer Titled “Pass It On, Until Every Woman Knows” Indianapolis, IN (PRWEB) March 06, 2014 The Diagnostics Marketing Association (DxMA) announced today its 2013 Marketer of the Year: Genomic Health. This award recognizes diagnostic industry innovation by marketers in highlighting their company and/or products and will be presented during the annual DxMA Global Marketing Summit to...


Word of the Day
baudekin
  • A rich embroidered or brocaded silk fabric woven originally with a warp of gold thread.
'Baudekin' seems to be an alternative form of 'baldachin,' from the Italian 'Baldacco,' Baghdad, the city where the material was made.
Related